Abstract: A class of benzoxazinone derivatives and a preparation method therefor, specifically related to a compound shown in formula (II), or a stereoisomer or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to a class of 5-substituted pyridine-2 (1H)-ketone compounds and a use thereof, and specifically relates to a compound as shown in formula (X) or a pharmaceutically acceptable salt thereof.

Abstract: A pyrrolotriazine compound, e.g., the compound of formula (II), a salt form thereof, a crystal form thereof, a preparation method therefor, and an application thereof are provided. An application in preparation of MNK1/2 inhibitor drugs and/or in preparation of drugs for treating colorectal cancer are also provided.

Abstract: Provided are a compound III serving as an LSD1 inhibitor and a crystal form thereof, as well as use of the compound and the crystal form thereof in preparation of a medicament for treating an LSD1 related disease.

Abstract: Disclosed are 6-carbamate substituted heteroaryl ring derivatives and a preparation method therefor. The present application particularly relates to a compound as shown in formula (II) and a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to a thiophene compound and an application thereof. The present invention specifically relates to a compound represented by formula (II) and a pharmaceutically acceptable salt thereof, wherein L1 is —C(?O)— or —C(?O)—NH—; R1 is R1a or aa; ring A is bb or cc; R1a is C1-3 alkyl substituted with 1, 2 or 3 Ra; and R3 is independently H, halogen or C1-3 alkoxy. The compound represented by formula (II) and the pharmaceutically acceptable salt thereof can better inhibit the activity of LSD1, further shows significant inhibitory activity against NCI-H1417 cell proliferation, and has good pharmacokinetic properties (including good oral bioavailability, oral exposure, half-life, and clearance rate, etc.).

Abstract: Provided is a compound as represented by formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: Substituted pyridazine phenol derivatives and a preparation method therefor, specifically relating to a compound as shown in formula (VI) and a pharmaceutically acceptable salt thereof, which can be used as an NLRP3 inhibitor.

Abstract: The present invention relates to a series of fused ring derivatives containing 1,4-oxazepane and a preparation method therefor, and in particular relates to a compound as shown in formula (II) and a pharmaceutically acceptable salt thereof.

Abstract: Disclosed is a salt form of an isoquinolinone type compound as a ROCK protein kinase inhibitor and a preparation method therefor, and use of the salt form in the preparation of a medicament for treating glaucoma or ocular hypertension is further included.

Abstract: Disclosed are an acetophenone oxime compound and a preparation method therefor, and specifically disclosed are a compound as shown in formula (II) and a pharmaceutically acceptable salt thereof.

Abstract: Disclosed are a series of benzo 2-azaspiro[4.4]nonane compounds, and specifically disclosed are a compound as represented by formula (P) or a pharmaceutically acceptable salt thereof.

Abstract: Salt types, crystal forms, and preparation methods for benzopyrazole compounds as RHO kinase inhibitors. Specifically, disclosed are hydrochloride and acetate of compounds of formula (I) and crystal forms thereof, as well as application of the salt types and the crystal forms in preparation of RHO inhibitor drugs.

Abstract: Provided is a cyclopropylamine compound as lysine-specific demethylase 1 (LSD1) inhibitor, and a use thereof in preparation of drug for treating diseases associated with LSD1. The cyclopropylamine compound is a compound represented by formula (I), an isomer thereof, and a pharmaceutically acceptable salt thereof.

Abstract: Disclosed are a series of benzo 2-azaspiro[4.4]nonane compounds, and specifically disclosed are a compound as represented by formula (P) or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed in the present invention are a series of tricyclic compounds, and particularly disclosed are a compound shown in formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed are a series of isoquinolone derivatives as ROCK protein kinase inhibitors and uses thereof in preparing medicaments for ROCK protein kinase inhibitor-related glaucoma or ocular hypertension diseases. Specially, disclosed are a compound of formula (I), an isomer thereof or a pharmaceutically acceptable salt thereof.

Abstract: Methods, systems, electronic devices, and computer-readable storage media for image normalization processing are provided. In one aspect, an image normalization processing method includes: normalizing a feature map by respectively using K normalization factors to obtain K candidate normalized feature maps; for each of the K normalization factors, determining a first weight value for the normalization factor; and determining a target normalized feature map corresponding to the feature map based on the candidate normalized feature map corresponding to each of the K normalization factors and the first weight value for each of the K normalization factors. The K candidate normalized feature maps and the K normalization factors have a one-to-one correspondence, and K is an integer greater than 1.

Abstract: A biaryl compound. Specifically disclosed is a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.